Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to -$22.5 million.

  • Integra Lifesciences Holdings' Change in Receivables rose 2171.48% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 14035.0%. This contributed to the annual value of -$7.4 million for FY2024, which is 6107.12% down from last year.
  • Integra Lifesciences Holdings' Change in Receivables amounted to -$22.5 million in Q3 2025, which was up 2171.48% from $28.0 million recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Change in Receivables peaked at $31.5 million during Q4 2024, and registered a low of -$28.8 million during Q3 2024.
  • Its 5-year average for Change in Receivables is -$69368.4, with a median of $3.1 million in 2022.
  • Over the last 5 years, Integra Lifesciences Holdings' Change in Receivables had its largest YoY gain of 678468.27% in 2024, and its largest YoY loss of 1273482.14% in 2024.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Change in Receivables stood at $10.2 million in 2021, then fell by 1.35% to $10.0 million in 2022, then tumbled by 95.45% to $457000.0 in 2023, then skyrocketed by 6784.68% to $31.5 million in 2024, then plummeted by 171.53% to -$22.5 million in 2025.
  • Its last three reported values are -$22.5 million in Q3 2025, $28.0 million for Q2 2025, and -$21.5 million during Q1 2025.